Alcohol Consumption Not Found to Impact Sustained Virologic Response for Patients with Hepatitis C
October 3rd 2023The study investigators said that restricting access to direct-acting antiviral therapy due to alcohol consumption could create unnecessary barriers for those with hepatitis C virus.
Read More
FDA Approves Nedosiran for Patients With Primary Hyperoxaluria Type 1
October 2nd 2023Nedosiran (Rivfloza; Novo Nordisk Inc) injection is designed to inhibit the expression of liver enzyme lactate dehydrogenases leading to oxalate overproduction in patients 9 years of age and older with PH1.
Read More
AI and Precision Medicine Are Changing What’s Possible for Breast Cancer Treatment
October 2nd 2023Ongoing studies utilizing large-scale health databases that incorporate environmental, lifestyle, biological, and phenotypic data may provide insight that leads to better cancer prevention and treatment.
Read More
Nobel Prize Awarded to Scientists Whose Work Led to Development of mRNA COVID-19 Vaccines
October 2nd 2023Katalin Karikó, PhD, and Drew Weissman, MD, PhD, win Nobel Prize for discoveries in the area of nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
Read More
Topline Data Demonstrate Survival Improvement With Amivantamab-vmjw for NSCLC
September 29th 2023The MARIPOSA study evaluated amivantamab-vmjw (Rybrevant; Janssen Pharmaceutical) in combination with lazertinib compared to osimertinib and compared to lazertinib monotherapy in the first-line treatment of EGFR-mutated non–small cell lung cancer.
Read More
Bridging the Gap: Industry-Academia Collaboration in Pharmacy
September 29th 2023The most persuasive reason for industry-academia collaboration is the many opportunities it opens for pharmacy students who may not have considered all the ways they can use their PharmD to serve the cause of humankind.
Read More
Lead Investigator Provides Insight Into FDA Approval of Momelotinib for Myelofibrosis
September 29th 2023Ruben A. Mesa, MD, FACP, discusses the results of the SIMPLIFY-1 and MOMENTUM trials and how the data led to the approval of momelotinib to treat intermediate or high-risk myelofibrosis in adult patients with anemia.
Watch